TherapeuticsMD, Inc. TXMD PHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.therapeuticsmd.com

Company Profile ↓

$2.14

+84.48% 1Y

Mkt Cap$24.77M

P/E-71.33

P/B0.94

52W High$2.77

52W Low$1.04

Book Value$2.33

EPS (TTM)$-0.03

Company Overview

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.20.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $3.02M (+71.6% YoY); net profit $-569.00K.
Trailing 12 Months Year-on-year growth — revenue -8.7%, earnings -80.6%.
5-Year Trend Long-term compounding — revenue CAGR 2.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	2.88%
1 Year:	-8.70%

Compounded Profit Growth

5 Years:	-
1 Year:	-80.60%

Stock Price Performance

1 Year:	+84.48%
6 Months:	-6.96%
3 Months:	+13.83%
1 Month:	+3.38%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 64% of range

$1.04 $2.77

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)50.29 · Neutral

Price Performance

1M+3.38%

3M+13.83%

6M-6.96%

1Y+84.48%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-71.33

Industry PE

24.83

Forward P/E

6.11

PEG Ratio

Book Value

$2.33

Price to Book

0.94

P/S

7.75

EV/EBITDA

-15.87

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

2.88%

Profit 5Y

Revenue (YoY)

-8.70%

Earnings (YoY)

-80.60%

Profitability & Returns

ROCE

-12.82%

ROE

-1.08%

ROA

-2.88%

Profit Margin

-6.64%

Op Margin

-32.22%

Gross Margin

100.00%

EPS (Latest Qtr)

$0.01

EPS (TTM)

$-0.03

Balance Sheet & Liquidity

Debt/Equity

0.20

Quick Ratio

2.65

Current Ratio

3.22

Debt

$5.56M

Total Assets

$37.58M

Current Assets

$15.26M

Working Capital

$9.66M

Ownership

Promoter Holding

9.04%

Chg in Prom Hold

1.59%

FII / Inst Holding

31.72%

Chg in FII Hold

-0.08%

Financial Snapshot

Enterprise Value

$24.77M

Total Revenue (TTM)

$3.27M

EBITDA

$-1.37M

Free Cash Flow

$896.62K

Operating Cash Flow

$3.12M

Shares Outstanding

11.57M

Gross Margin

100.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TXMD TherapeuticsMD, Inc. PHARMA	2.14	-71.33	$24.77M	0.00%	-12.82%	-1.08%	2.88%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	3.98M	4.25M	4.42M	4.12M	3.77M	3.76M	3.47M	5.09M	3.95M	6.08M	23.72M	15.90M	12.25M	10.70M	19.34M	22.58M	19.87M	23.00M	25.41M	18.68M	695.00K	348.00K	354.00K	416.00K	437.00K	-53.00K	-	-	-	393.00K	952.00K	784.00K	893.00K	724.00K
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	4.00M	4.39M	3.82M	3.27M	4.30M	3.78M	3.33M	3.57M	3.72M	3.53M	3.14M	3.31M	2.77M	4.14M	3.18M	4.83M	22.27M	13.02M	9.54M	6.30M	16.06M	17.00M	15.18M	18.87M	20.12M	13.94M	14.47M	0	0	416.00K	437.00K	-53.00K	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.59M	1.65M	1.61M	2.39M	1.45M
Operating Income	-19.50M	-	-20.97M	-21.21M	-25.13M	-	-21.29M	-19.83M	-14.83M	-	-24.72M	-33.02M	-34.36M	-	-38.11M	-41.64M	-27.07M	-	-50.92M	-45.04M	-24.97M	-34.61M	-29.28M	-35.18M	-39.92M	-35.39M	-17.88M	-14.86M	-14.52M	-2.67M	-2.47M	-1.77M	-1.14M	-2.79M	-1.13M	-1.19M	-695.00K	-830.00K	-1.50M	-723.00K
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.10M	643.00K	149.00K	-3.24M	-629.00K
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00K	2.00K	3.00K	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-668.00K	545.00K	50.00K	-580.00K	103.00K
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-32.00K	0	0	32.00K	0
Net Income	-19.47M	-17.48M	-20.93M	-21.09M	-25.02M	-22.84M	-21.16M	-19.68M	-14.66M	-21.43M	-24.40M	-33.22M	-35.60M	-39.39M	-39.51M	-55.24M	-31.97M	-49.44M	-56.85M	-51.98M	-32.61M	-42.09M	-39.38M	-42.65M	-47.42M	-42.96M	-49.02M	112.28M	-28.96M	-3.60M	-2.41M	-3.38M	-734.00K	-1.09M	-609.00K	-653.00K	551.00K	152.00K	-619.00K	95.00K
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5.41	-5.62	-	-5.70	12.83	-3.13	-0.37	-0.24	-0.32	-0.06	-0.09	-0.05	-0.06	0.05	0.01	-	0.01
R&D Expense	16.42M	-	15.10M	13.84M	14.66M	-	7.72M	8.72M	6.44M	-	7.04M	6.80M	6.71M	-	6.32M	4.96M	4.08M	-	3.27M	2.74M	2.03M	-	2.05M	2.01M	1.60M	-	1.40M	1.58M	1.11M	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	2.09M	3.82M	8.78M	15.03M	20.14M	19.36M	16.78M	16.10M	49.65M	64.87M	-	69.96M	1.30M	1.76M	3.02M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	1.40M	1.40M	0	-	-
Gross Profit	-	1.14M	2.47M	6.82M	11.35M	15.64M	15.17M	14.14M	13.36M	43.31M	48.90M	1.17M	68.57M	1.30M	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	57.90M	9.82M	6.61M	7.24M
Operating Income	-	-5.43M	-16.15M	-25.81M	-54.04M	-85.19M	-90.25M	-77.63M	-130.22M	-151.21M	-155.54M	-	10.66M	-8.52M	-4.84M	-4.21M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	11.86M	-7.60M	-3.56M	-3.02M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	22.57M	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	1.07M	-7.74M	-2.34M	-653.00K
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	0	-43.00K	-31.00K	0
Net Income	-2.87M	-12.91M	-35.12M	-28.42M	-54.22M	-85.08M	-89.88M	-76.93M	-132.62M	-176.15M	-183.52M	-	112.00M	-10.28M	-2.18M	-569.00K
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	11.96	-0.98	-0.19	-0.05
R&D Expense	-	107.24K	4.49M	13.55M	43.22M	72.04M	53.94M	33.85M	27.30M	19.79M	10.43M	7.09M	-	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	1.44M	5.93M	62.02M	59.08M	73.73M	142.47M	143.23M	211.98M	265.99M	181.61M	-	90.46M	43.31M	38.82M	37.66M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	55.35M	11.80M	12.26M	14.45M
Cash & Equivalents	-	422.94K	126.42K	-	-	-	-	-	-	-	-	-	-	38.07M	4.33M	5.06M	7.48M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	7.62M	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	36.18M	-	-	-	-
Total Liabilities	-	-	3.15M	7.36M	7.32M	-	-	-	13.32M	114.46M	256.78M	305.61M	-	55.31M	14.02M	11.45M	10.78M
Current Liabilities	-	-	3.15M	3.62M	7.32M	10.69M	10.67M	14.98M	13.32M	41.08M	53.00M	59.24M	-	46.84M	6.85M	5.17M	4.79M
Long Term Debt	-	-	-	-	-	-	-	-	-	73.38M	194.63M	237.70M	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	8.76M	8.01M	7.17M	6.10M
Total Equity	483.63K	964.41K	-1.71M	-1.43M	54.70M	48.39M	63.06M	127.49M	129.91M	97.52M	9.20M	-124.00M	-	35.14M	29.29M	27.37M	26.88M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	9.50M	11.53M	11.53M	11.57M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-4.97M	-12.74M	-20.77M	-45.52M	-79.04M	-69.14M	-76.16M	-106.81M	-165.72M	-159.47M	-	9.36M	-23.08M	1.17M	2.45M
Investing Cash Flow	-37.64K	-272.51K	-583.56K	-606.76K	-584.36K	-1.26M	-827.11K	-21.50M	-23.89M	-1.60M	-2.22M	-355.00K	0	-	-
Financing Cash Flow	4.71M	14.44M	73.99M	43.30M	92.97M	137.23M	72.58M	162.79M	188.83M	80.72M	129.55M	-235.21M	3.15M	0	-
Capital Expenditure	-28.77K	-66.41K	-40.79K	-30.96K	-165.26K	-396.15K	-61.82K	-217.04K	-2.45M	-207.00K	-2.22M	-355.00K	-	-	-
Free Cash Flow	-5.00M	-12.80M	-20.81M	-45.55M	-79.21M	-69.54M	-76.22M	-107.03M	-168.17M	-159.68M	-	9.00M	-23.08M	1.17M	2.45M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-15.80M	-44.99M	732.00K	2.42M

Ratios (Annual)

Figures in %.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	54.6%	64.7%	77.7%	75.6%	77.6%	78.4%	84.3%	83.0%	87.2%	75.4%	-	98.0%	100.0%	-	-
Operating Margin %	-	-259.9%	-423.0%	-294.1%	-359.6%	-422.9%	-466.3%	-462.7%	-808.8%	-304.6%	-239.8%	-	15.2%	-654.6%	-275.1%	-139.4%
Net Margin %	-	-618.4%	-919.9%	-323.8%	-360.8%	-422.4%	-464.3%	-458.5%	-823.7%	-354.8%	-282.9%	-	160.1%	-789.4%	-123.9%	-18.8%
ROE %	-297.3%	754.3%	2,450.6%	-52.0%	-112.0%	-134.9%	-70.5%	-59.2%	-136.0%	-1,914.4%	148.0%	-	318.7%	-35.1%	-8.0%	-2.1%
ROCE %	-	317.0%	-700.2%	-47.2%	-111.7%	-135.1%	-70.8%	-59.8%	-76.2%	-71.0%	-127.1%	-	24.4%	-23.4%	-14.4%	-12.8%

Shareholding Pattern

Insiders

9.04%

Institutions

31.72%

Public Float

34.88%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Rubric Capital Management LP	10.30%	1.19M	$2.61M
2	Clearline Capital, LP	5.49%	635.22K	$1.39M
3	Vanguard Capital Management LLC	3.06%	353.70K	$774.60K
4	Tejara Capital Ltd	2.98%	344.48K	$754.41K
5	Adar1 Capital Management, LLC	2.96%	342.45K	$749.96K
6	Renaissance Technologies, LLC	1.27%	146.60K	$321.05K
7	Morgan Stanley	1.12%	129.22K	$282.99K
8	Blackrock Inc.	0.99%	115.14K	$252.17K
9	Geode Capital Management, LLC	0.91%	105.85K	$231.81K
10	Citadel Advisors Llc	0.74%	86.09K	$188.55K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TXMD

Google News Sat, 30 May 2026

TXMD - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5YWEpIcnRuMW9DaEhtbVl3UUpoSFJRRnZCNkxtS214a1hmb2dDOTJZNzR0dXhFWGZMam1NLS1YTzhTVFFrcWc?oc=5" target="_blank">TXMD</a>  <font color="#6f6f6f">Finviz</font>…

Google News ue, 11 Aug 2026

TherapeuticsMD to Recognize About $365K IMVEXXY Milestone in Q3 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNZWF0ZnlFMi00NlluLWpHQk1wMUFaUF9RYnJTX0U2cUNGNG9jVzBZQ19uU092OHh4S01OOEh2M0FxamthRE1oRnRIYjk0ZElBbFVFUTJPUGpWaXhCYTFWNlROcDl1c1I4LWl3OE9sYTZ4eFlDaVFfMTN5dkNhNUxPc1JEdV9SREVjZlNycH…

Google News ue, 25 Aug 2026

THERAPEUTICSMD STOCK : BIG PRICE RECOVERY | TXMD STOCK Moon (nkL8YZ0GKj) - Mshale

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5jTHFNbUxyUjJNMlhSUkhpS1MxUUVBNFN3WGpvbjBQNGNLSGx0aF9KT181UFNBVnJtX2podFIxallrVjRMOHNpN3dlaE1zdjZJcTdEcWk4dDlMNWs?oc=5" target="_blank">THERAPEUTICSMD STOCK : BIG PRICE RECOVERY | …

Google News Fri, 21 Aug 2026

TherapeuticsMD (TXMD) Range: Moves 0.49% Down to $2.05; the Current Price Sits Inside the Supplied Technical Range for the Current Session - Dealer Gamma - siam.in

<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxOSkdFNGQ0bWh6b1ZHXzNRSnl4VFZXQXJuVDNTbFFuU3FoYk5ZczM5TTBFVDd2VlYtYld4YzhhbHBrNmFETG53emp5SHctVWdwVUxFeU85TTFELXczUDVVLTMwNm1IMzdFU3hfRC1BSWpMREEwamVWM1RBc252ODVjY2ZyZWdWX2NlN0RwWV…

Google News Wed, 30 Aug 2023

symbol__ Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBEU2dwOGFoLW81NU1scFN5c0d6MkZyYmNBWEg3OXN1d1piN2lRNWxyYUFTTnc0VVI2UmJUdnV1VHJpaWhXcTlRZ0pTUVoyZVoz?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a>  <fon…

Google News Mon, 27 Jul 2026

TherapeuticsMD Inc (TXMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE51UzJJRTVTc0FWSHdac2s4VkUzV283dDdZZDcwQXBxOHpFQXIxcVcxUjlQa1lKekNIRE10Smp4cEc2d3NlWmU5RHRCWXRfblFpYnZYZEFUM2pEMjIyQTF6cmJnbzN4VGM?oc=5" target="_blank">TherapeuticsMD Inc (TXMD) Sh…

TXMD — Frequently Asked Questions

What is the current share price of TherapeuticsMD, Inc. (TXMD)?

As of 2026-09-19 21:16 PDT, TherapeuticsMD, Inc. (TXMD) trades at $2.14 on NasdaqGS. Its 52-week range is $1.04 to $2.77.

What is the market capitalisation of TXMD?

TherapeuticsMD, Inc. (TXMD) has a market capitalisation of $24.77M on NasdaqGS.

What is the P/E ratio of TXMD?

TXMD trades at a trailing price-to-earnings (P/E) ratio of -71.33. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.94.

What is the return on equity (ROE) of TXMD?

TXMD has a return on equity (ROE) of -1.08%. Its return on capital employed (ROCE) is -12.82%.

Is TXMD a good stock to buy?

This page provides a data-driven analysis of TherapeuticsMD, Inc. (TXMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

TherapeuticsMD, Inc. TXMD PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

TXMD - Finviz

TherapeuticsMD to Recognize About $365K IMVEXXY Milestone in Q3 - Stock Titan

THERAPEUTICSMD STOCK : BIG PRICE RECOVERY | TXMD STOCK Moon (nkL8YZ0GKj) - Mshale

TherapeuticsMD (TXMD) Range: Moves 0.49% Down to $2.05; the Current Price Sits Inside the Supplied Technical Range for the Current Session - Dealer Gamma - siam.in

symbol__ Stock Quote Price and Forecast - CNN

TherapeuticsMD Inc (TXMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

TXMD — Frequently Asked Questions

What is the current share price of TherapeuticsMD, Inc. (TXMD)?

What is the market capitalisation of TXMD?

What is the P/E ratio of TXMD?

What is the return on equity (ROE) of TXMD?

Is TXMD a good stock to buy?

Explore More